Skip to content
Flyout Menu
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    • Discovery
      • CADD & Structural Biology
      • Compound Management
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vitro Biology
      • In Vivo Pharmacology
      • Integrated Drug Discovery (IDD)
      • Safety & Toxicology
      • Synthetic & Medicinal Chemistry
    • Drug Substance Development
      • Analytical Development
      • Developability & Pre-Formulation
      • Particle Science & Engineering
      • Process Development
      • Process Engineering
      • Discovery Process Chemistry
    • Drug Substance Manufacturing
      • Engineering Technologies
      • Infrastructure
      • Product Types
    • New Modalities
      • Antibody–Drug Conjugates
      • Lipids
      • Oligos
      • Peptides
    • Formulations
      • Clinical Formulation Supplies
      • New Chemical Entity (NCE) formulation development
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Newsroom – Blogs
    • Newsroom – Case Studies
  • Investors
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us

Disclosures

Overview

Our commitment to scientific excellence, operational efficiency, and customer focus positions us as a preferred partner in the industry. In this section, we highlight how Sai Life Sciences drives growth through strategic investments in infrastructure, technology and talent, all aimed at delivering value to our stakeholders.

Financial Information
Annual Reports
Corporate Governance
Shareholder Service
Disclosures

Disclosure under regulation 30

Key items

Download

Investor Meeting Intimation-3rd and 4th June 2026

Download

Allotment of Equity Shares-14.05.2026

Download

Press Release-Achievement of 100% Renewable Power at Bidar

Download

Allotment of Equity Shares-23.04.2026

Download

Change in Management-Appointment of Dr John Pavey as SMP

Download

Allotment of Equity Shares – 24.03.2026

Download

Investor Meeting Intimation-13.03.2026

Download

Revised Allotment of Equity Shares – 26.02.2026

Download

Credit Rating Letter – ICRA Limited – 26.02.2026

Download

Allotment of Equity Shares – 22.02.2026

Download

Allotment of Equity Shares – 05.02.2026

Download

Press Release-Strategic Collaboration with Mabtech

Download

Allotment of Equity Shares -19.12.2025

Download

Investor Meeting Intimation-27.11.2025

Download

10.03.2025 ESOP conversion into Equity

Download

Allotment of Equity Shares – 16.09.2025

Download

Allotment of Equity Shares – 03.09.2025

Download

Allotment of Equity Shares – 04.11.2025

Download

Allotment of Equity Shares – 08.12.2025

Download

Allotment of Equity Shares – 16.09.2025

Download

Allotment of Equity Shares – 17.10.2025

Download

Allotment of Equity Shares – 19.12.2025

Download

Allotment of Equity Shares – 22.11.2025

Download

Allotment of Equity Shares – 23.04.2025

Download

Allotment of Equity Shares – 23.07.2025

Download

Allotment of Equity Shares – 23.08.2025

Download

Allotment of Equity Shares on conversion of ESOP

Download

Allotment of Securities 13.05.2025

Download

Alottment of Shares – 26.06.2025

Download

Change in Designation of SMP

Download

Clarification pertaining to the Proposed Resolutions-AGM_02.09.2025

Download

Clarification pertaining to the Proposed Resolutions-AGM_03.09.2025

Download

Commencement_Of_Commercial_Operation_Second_Phase_Bidar_Facility

Download

Corrigendum to the Notice of the 26th AGM

Download

Form MGT-7-FY 2024-25

Download

Investor Meet Intimation ALF Accurate

Download

Investor Meet Intimation Kotak 18th Feb

Download

Investor Meet Intimation Kotak

Download

Investor Meet Intimation with Capital Group Investment Management

Download

Investor Meeting Intimation_18 and 19_Sep_2025

Download

Investor Meeting Intimation 19 and 20 November 2025

Download

Investor Meeting Intimation-27.11.2025

Download

Outcome of Board Meeting – 06 February 2025

Download

Press Release – Sustainability Report FY 2024-25

Download

Press Release for Integrated CMC partnership

Download

Press Release for Veterinary API-Unit VI Bidar

Download

Press Release regarding Recruitment Drive for 200 Scientists

Download

Press Release to Double Process R&D Capacity with New Facility-Hyderabad

Download

Proposed Capacity Addition

Download

Reg 30 App of Siva as Director

Download

Reg 30 Change in Management and Allotment of Shares 24.03.2025

Download

Reg 30 IT Demand Notice

Download

Reg 30 Order MHVAT

Download

Reg 30 Resignation of Mitesh Daga

Download

Reg30 SEBI Allotment of Equity Shares 20.03.2025

Download

Revised_Alottment_of_Shares_27.06.2025

Download

Sai_Investor_Meeting_Intimation_24_Sep_2025

Download

Sai Meeting Intimation 13 and 14 August 2025 Avendus Spark INDX

Download

Sai_Meeting_Intimation_04062025_Emkay_Global

Download

Sai_Meeting_Intimation_04062025_Group_Meeting_11AM

Download

Sai_Meeting_Intimation_04062025_Group_Meeting_12PM

Download

Sai_Meeting_Intimation_04062025_Group_Meeting_145PM

Download

Sai_Meeting_Intimation_06032025_1 PGIM

Download

Sai_Meeting_Intimation_06032025_2 Nippon Life India

Download

Sai_Meeting_Intimation_06032025_4 Aditya Birla Sun Life

Download

Sai_Meeting_Intimation_06032025_5 DSP

Download

Sai_Meeting_Intimation_06032025_6 BlackRock

Download

Sai_Meeting_Intimation_07032025 Creaegis

Download

Sai_Meeting_Intimation_11062025_C_Worldwide_Asset_Management

Download

Sai_Meeting_Intimation_17062025_Group_Meeting

Download

Sai_Meeting_Intimation_19062025_Group_Meeting

Download

Sai_Meeting_Intimation_24062025_IIFLs-Invest-India

Download

Sai_Meeting_Intimation_25032025_1 Goldman Sachs

Download

Sai_Meeting_Intimation_25032025_2 T. Rowe

Download

Sai_Meeting_Intimation_25032025_3 Amansa

Download

Sai_Meeting_Intimation_26032025_1 Ward Ferry

Download

Sai_Meeting_Intimation_26032025_2 GIC

Download

Sai_Meeting_Intimation_26032025_3 M&G Investments

Download

Sai_Meeting_Intimation_26032025_4 White Oak

Download

Sai_Meeting_Intimation_26032025_5 Fidelity

Download

Sai_Meeting_Intimation_26032025_6 Capital Research

Download

Sai_Meeting_Intimation_27032025_1 Franklin Templeton

Download

Sai_Meeting_Intimation_27032025_2 Eastspring

Download

Sai_Meeting_Intimation_27032025_3 Qatar

Download

Sai_Meeting_Intimation_27032025_4 Capital World

Download

Sai_Meeting_Intimation_27032025_5 Kotak Offshore

Download

Sai_Meeting_Intimation_28032025_1 DSP

Download

Sai_Meeting_Intimation_28032025_2 Invesco

Download

Sai_Meeting_Intimation_28032025_3 Aditya Birla Capital

Download

Sai_Meeting_Intimation_28032025_4 Enam

Download

Sai_Meeting_Intimation_28032025_5 HDFC Asset

Download

Sai_Meeting_Intimation_30052025_Columbia_Threadneedle

Download

Disclosure under regulation 46

Key items

Download

Annual Secretarial Compliance Report-FY 2025-26

Download

Statement of Deviation-31.03.2026

Download

Statement of Deviation-31.12.2025

Download

Statement of Deviation-30.09.2025

Download

Statement of Deviation-30.06.2025

Download

Statement of Deviation-31.03.2025

Download

Monitoring Agency Report – 31 March 2026

Download

Outcome of Board Meeting – 14 May 2026

Download

Key Performance Indicators-FY 2025-26

Download

Annual Secretarial Compliance Report- FY 2024-25

Download

Monitoring Agency Report – 31 December 2025

Download

Outcome of Board Meeting – 05 February 2026

Download

26th AGM Proceedings

Download

26th AGM-Voting Results and Scrutinizer’s Report

Download

Monitoring agency report – Dec 31st 2024

Download

Statement of deviation – Dec 31st 2024

Download

Credit Rating – 14 August 2025

Download

Credit Rating 15 May 2024

Download

ESOP Scheme 2008

Download

ESOP Scheme 2018

Download

Form MGT-7-FY 2024-25

Download

Investor contact

Download

Monitoring Agency Report – 30 June, 2025

Download

Monitoring Agency Report – 30 September 2025

Download

Monitoring agency report – Mar 31st 2025

Download

Newspaper Advertisements – Results for Mar 31st 2025

Download

Newspaper Advertisements – Postal Ballot

Download

Newspaper Advertisements – 26th AGM

Download

Notice of 26th AGM – 11 September 2025

Download

Notice of Postal Ballot – 15th May 2025

Download

Details of Business

Download

Outcome of Board Meeting – 06 November 2025

Download

Outcome of Board Meeting – 07 August 2025

Download

Outcome of Board Meeting – 13 May 2025

Download

Postal Ballot – Outcome and Scrutinizer report

Download

Financial Results – Quarter ending December 2024

Download

Newspaper Advertisements – Results for Dec 31st 2024

Download

DS-7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India

Company
Main Menu
  • About Us
  • Investors
  • Careers
  • Contact us
Our Capabilities
Main Menu
  • Discovery
  • Drug Substance Development
  • Drug Substance Manufacturing
  • Formulations
  • New Modalities
Knowledge Hub
Main Menu
  • News
  • Blogs
  • Case Studies
Legal
Main Menu
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions

© 2026 Sai Life Sciences All rights reserved.

Facebook-f Instagram Linkedin-in X-twitter Youtube